Cultures, products and methods using umbilical cord matrix cells
View Patent ↗Stem cells from human sources can have a variety of useful applications in disease treatment and biotechnology. More particularly the umbilical cord matrix cell cultures of the invention have a variety of totipotent, pluripotent, or multipotent cells for a variety of end uses from a non-controversial, universally available, species-specific source. The technology can have application to any amniotic animal, including agricultural and laboratory animals and humans. The invention relates to isolating the stem cells, culturing the stem cells, maintaining the stem cells, transforming the stem cells into useful cell types using genetic or other transformation technologies, stem cell and tissue banking and using untransformed or transformed cells in disease treatment.
1. A method of reducing motor dysfunction associated with Parkinson's disease in a patient with Parkinson's disease comprising:
a) enzymatically dispersing umbilical cord matrix to provide enzymatically dispersed umbilical cord matrix cells;
b) culturing the enzymatically dispersed umbilical cord matrix cells in the presence of epidermal growth factor (EGF) and platelet derived growth factor (PDGF) to proliferate the umbilical cord matrix cells;
c) culturing the enzymatically dispersed umbilical cord matrix cells on a substrate surface and removing non-adherent cells;
d) culturing adherent cells from (c) to select for a population of umbilical cord matrix cells that comprise cells that are negative for CD34 and CD45, positive for telomerase activity, can be expanded in vitro, and maintained in culture through repeated passages;
e) isolating the adherent cells from d);
f) introducing the isolated adherent cells from e) into the substantia nigra region of the midbrain striatum in a patient with Parkinson's disease, and
g) allowing the cells to integrate into the substantia nigra region of the midbrain striatum of the patient whereby motor dysfunction associated with Parkinson's disease in the patient is reduced.
2. The method of claim 1 , wherein the umbilical cord matrix cells comprise a foreign gene.